Literature DB >> 23917954

Spondyloarthritis. Treat-to-target in spondyloarthritis--do we have a plan?

Walter P Maksymowych1.   

Abstract

Clinicians now have the therapies and outcome tools to implement treat-to-target strategies aimed at achieving and maintaining adequate function and control of symptoms in spondyloarthritis and psoriatic arthritis. However, validation of surrogate markers of structural progression is a prerequisite for treat-to-target strategies aimed at improving long-term outcomes such as joint damage.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23917954     DOI： 10.1038/nrrheum.2013.123

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  11 in total

1.  Consensus statement on the use of rituximab in patients with rheumatoid arthritis.

Authors:  J S Smolen; E C Keystone; P Emery; F C Breedveld; N Betteridge; G R Burmester; M Dougados; G Ferraccioli; U Jaeger; L Klareskog; T K Kvien; E Martin-Mola; K Pavelka
Journal:  Ann Rheum Dis       Date:  2006-10-26       Impact factor: 19.103

2.  Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification.

Authors:  Walter P Maksymowych; Nathalie Morency; Barbara Conner-Spady; Robert G Lambert
Journal:  Ann Rheum Dis       Date:  2012-05-05       Impact factor: 19.103

3.  Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?

Authors:  Uta Kiltz; Xenofon Baraliakos; Pantelis Karakostas; Manfred Igelmann; Ludwig Kalthoff; Claudia Klink; Dietmar Krause; Elmar Schmitz-Bortz; Martina Flörecke; Matthias Bollow; Jürgen Braun
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-09       Impact factor: 4.794

4.  Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study.

Authors:  Yukitomo Urata; Ryoko Uesato; Dai Tanaka; Yoshihide Nakamura; Shigeru Motomura
Journal:  Ann Rheum Dis       Date:  2011-10-21       Impact factor: 19.103

5.  Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design.

Authors:  Walter P Maksymowych; Oliver Fitzgerald; George A Wells; Dafna D Gladman; Robert Landewé; Mikkel Ostergaard; William J Taylor; Robin Christensen; Paul-Peter Tak; Maarten Boers; Silje W Syversen; Joan M Bathon; Christopher J Ritchlin; Philip J Mease; Vivien P Bykerk; Patrick Garnero; Piet Geusens; Hani El-Gabalawy; Daniel Aletaha; Robert D Inman; Virginia Byers Kraus; Tore K Kvien; Désirée van der Heijde
Journal:  J Rheumatol       Date:  2009-08       Impact factor: 4.666

6.  Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study.

Authors:  Robert G W Lambert; David Salonen; Proton Rahman; Robert D Inman; Robert L Wong; Steven G Einstein; Glen T D Thomson; Andre Beaulieu; Denis Choquette; Walter P Maksymowych
Journal:  Arthritis Rheum       Date:  2007-12

7.  Treating rheumatoid arthritis to target: recommendations of an international task force.

Authors:  Josef S Smolen; Daniel Aletaha; Johannes W J Bijlsma; Ferdinand C Breedveld; Dimitrios Boumpas; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Maarten de Wit; Maxime Dougados; Paul Emery; Alan Gibofsky; Juan Jesus Gomez-Reino; Boulos Haraoui; Joachim Kalden; Edward C Keystone; Tore K Kvien; Iain McInnes; Emilio Martin-Mola; Carlomaurizio Montecucco; Monika Schoels; Désirée van der Heijde; Desirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-03-09       Impact factor: 19.103

Review 8.  Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis.

Authors:  M M Schoels; J Braun; M Dougados; P Emery; O Fitzgerald; A Kavanaugh; T K Kvien; R Landewé; T Luger; P Mease; I Olivieri; J Reveille; C Ritchlin; M Rudwaleit; J Sieper; J S Smolen; M de Wit; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2013-06-05       Impact factor: 19.103

9.  Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.

Authors:  Josef S Smolen; Jürgen Braun; Maxime Dougados; Paul Emery; Oliver Fitzgerald; Philip Helliwell; Arthur Kavanaugh; Tore K Kvien; Robert Landewé; Thomas Luger; Philip Mease; Ignazio Olivieri; John Reveille; Christopher Ritchlin; Martin Rudwaleit; Monika Schoels; Joachim Sieper; Martinus de Wit; Xenofon Baraliakos; Neil Betteridge; Ruben Burgos-Vargas; Eduardo Collantes-Estevez; Atul Deodhar; Dirk Elewaut; Laure Gossec; Merryn Jongkees; Mara Maccarone; Kurt Redlich; Filip van den Bosch; James Cheng-Chung Wei; Kevin Winthrop; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2013-06-08       Impact factor: 19.103

10.  Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years.

Authors:  Désirée van der Heijde; David Salonen; Barbara N Weissman; Robert Landewé; Walter P Maksymowych; Hartmut Kupper; Shaila Ballal; Eric Gibson; Robert Wong
Journal:  Arthritis Res Ther       Date:  2009-08-24       Impact factor: 5.156
View more
  4 in total

Review 1.  Therapies of Early, Advanced, and Late Onset Forms of Axial Spondyloarthritis, and the Need for Treat to Target Strategies.

Authors:  Nurullah Akkoc; Gercek Can; Salvatore D'Angelo; Angela Padula; Ignazio Olivieri
Journal:  Curr Rheumatol Rep       Date:  2017-02       Impact factor: 4.592

2.  Comment on "treat-to-target in spondyloarthritis: implications for clinical trial designs".

Authors:  Daniel Wendling; Clément Prati
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

3.  Author's reply to Wendling and Prati: "treat-to-target in spondyloarthritis: implications for clinical trial designs".

Authors:  James Cheng-Chung Wei
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

4.  IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients.

Authors:  Fernanda Manente Milanez; Carla G S Saad; Vilma T Viana; Júlio C B Moraes; Grégory Vinícius Périco; Percival Degrava Sampaio-Barros; Célio R Goncalves; Eloísa Bonfá
Journal:  Arthritis Res Ther       Date:  2016-02-24       Impact factor: 5.156
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.